Search

Your search keyword '"Kambiz, Rahbar"' showing total 192 results

Search Constraints

Start Over You searched for: Author "Kambiz, Rahbar" Remove constraint Author: "Kambiz, Rahbar"
192 results on '"Kambiz, Rahbar"'

Search Results

1. Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET

2. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialResearch in context

7. Digital Image Enhancement Through Bi-Histogram Equalization Using Entropy-Based Plateau Limit

8. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

10. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

11. Bone Age Assessment Using Content-Based Image Retrieval System Using VGG-19 Deep Neural Network

12. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

13. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

17. Safety and Survival Outcomes of177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior223Ra treatment: The RALU Study

18. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

19. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis

21. PSMA Theranostics: Current Status and Future Directions

22. Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms

24. [18F]-PSMA-1007-PET for evaluation of kidney function

27. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

28. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

30. Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

31. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions

32. PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor

33. Development and validation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection

34. Prediction of early prostate cancer recurrence using a liquid biopsy approach

35. Time interval between radium-223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study

36. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy

37. Somatostatin Receptor–Targeted Radioligand Therapy in Head and Neck Paraganglioma

39. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

40. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence

41. Lokale Therapieverfahren neuroendokriner Tumoren mit dem Schwerpunkt nuklearmedizinische Optionen

42. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy

43. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

44. PSMA radioligand therapy in patients with advanced prostate cancer

45. Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer

46. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

47. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trial

48. Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra) : Interim analysis of the RALU study

49. Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer : Results from the VISION trial sub-study

50. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer : preliminary data on immunohistochemistry and PET imaging

Catalog

Books, media, physical & digital resources